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ABSTRACT OF THESIS 
 
 
CANCER PATIENTS’ TOBACCO USE AND TOBACCO TREATMENT REFERRAL 
RESPONSE: IMPLEMENTATION OUTCOMES AT A NATIONAL CANCER 
INSTITUTE-DESIGNATED CANCER CENTER 
 
Smoking after cancer diagnosis is linked to cancer-specific and all-cause mortality 
among other adverse outcomes. Yet, 10-20% of U.S. cancer survivors are current 
smokers. Implementation of evidence-based tobacco treatment in cancer care facilities is 
widely recommended, yet rarely accomplished. This study focuses on the early outcomes 
of a tobacco treatment program integrated within an NCI-designated cancer center. 
Participants consist of 26,365 patients seen at the cancer center during the first 18 months 
of implementation. The study is a retrospective chart review of patients’ tobacco use, and 
among current users, patients’ treatment referral response. Over 99% of patients were 
screened for tobacco use. Current use occurred in 21.05% of patients; cigarettes were the 
most popular product. Only 17.22% of current users accepted a referral for tobacco 
treatment; among the 76.59% of current users who declined, the majority were “not ready 
to quit” or wanted to quit “on their own”. Multiple demographic and clinical variables 
were associated with tobacco use and treatment referral response outcomes. Despite 
cancer diagnosis presenting a “teachable moment” for tobacco cessation, many cancer 
patients may not be ready to quit. Clinically proven strategies to increase motivation, 
prompt quit attempts and encourage treatment use are warranted in cancer settings. 
KEYWORDS: Cancer Patients, Program Evaluation, Smoking, Tobacco Use, Tobacco 
Treatment  
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CHAPTER 1. INTRODUCTION 
The 2014 U.S. Surgeon General’s Report on Smoking (US Department of Health 
and Human Services, 2014) clearly articulates that cancer survivors’ cigarette smoking 
plays a causal role in numerous adverse outcomes. This report demonstrated that smoking 
after cancer diagnosis is causally associated with higher rates of all-cause mortality, 
cancer-specific mortality, and second primary plus increased risk of recurrence, poor 
treatment response, and severe treatment-related toxicity. Additionally, smokers are 
significantly more likely than non-smokers to have post-surgical complications (e.g., 
infection, reintubation), longer hospital stays, and a requisite return to the operating room 
(Gajdos et al., 2012; Hatcher et al., 2017). Cancer survivors who smoke also report worse 
quality of life (e.g., greater psychological distress, less physical function) than former and 
never smokers (Aigner et al., 2016; Mesquita et al., 2015). It is now undeniable that 
smoking undermines the health of cancer survivors. 
Many U.S. cancer survivors continue to smoke after their cancer diagnosis. In one 
recent study with Health Information National Trends Survey data (n = 33,525), 16% of 
cancer survivors reported smoking some days or everyday (Swoboda, Walker, & Huerta, 
2019). Similarly, other population-based surveys (n = 2,060-2,527) find that 9-19% of 
cancer survivors are current smokers (Gallaway et al., 2019; Mayer & Carlson, 2011; 
Westmaas, Alcaraz, Berg, & Stein, 2014). Prevalence estimates are even higher if one 
focuses on individuals who were smoking at cancer diagnosis. For instance, data from a 
National Health and Nutrition Examination Survey (n = 2,374) showed 64% of cancer 
survivors who smoked at diagnosis continue to smoke (Tseng, Lin, Moody-Thomas, 
Martin, & Chen, 2012), a finding that closely mirrors the results of a systematic literature 
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review on lung and head/neck cancer survivors (Burris, Studts, DeRosa, & Ostroff, 
2015). Aggregating data across studies, it seems 10-20% of all cancer survivors smoke, 
with higher prevalence rates in subgroups of the patient population.  
Due to the profound risks of smoking after cancer diagnosis, most guidelines for 
cancer survivors’ health promotion recommend tobacco abstinence (Centers for Disease 
Control and Prevention, 2004; Doyle et al., 2009; R. Smith et al., 2017). Guidelines also 
exist for hospitals and clinics to follow in their care of cancer survivors (Hanna, 2013; 
International Society of Nurses in Cancer Care, 2014; Toll, Brandon, Gritz, Warren, & 
Herbst, 2013). For example, the National Comprehensive Cancer Network (NCCN) 
Clinical Practice Guidelines for Smoking Cessation state tobacco treatment should be 
standard of care, integrated throughout the cancer care process from work-up and 
diagnosis to curative treatment and end-of-life care (Shields et al., 2018). To facilitate 
this, the NCCN (Shields et al., 2018) recommends that smoking status should be asked of 
every cancer patient at every visit, and responses should be documented in the electronic 
medical record (EMR). Similarly, the American Association for Cancer Research 
(AACR) has a policy statement that includes universal assessment and documentation of 
tobacco use as standard of cancer care (Toll et al., 2013). Furthermore, the AACR policy 
statement says cancer care providers should receive proper training in tobacco treatment 
and be incentivized at the system level for referral to and delivery of said treatment. 
Compliance with the NCCN, AACR and similar widely espoused guidelines would 
facilitate health promotion among cancer survivors, but these mandates are not being met. 
Indeed, the results of U.S. cancer care provider surveys (n = 1,197-1,507) found that 
while 90% ask about tobacco use and 80% advise tobacco cessation, only 40-45% discuss 
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treatment options and provide assistance (Warren, Kasza, Reid, Cummings, & Marshall, 
2013; Warren, Marshall, et al., 2013). Similarly, a recent literature review revealed that 
fewer than 75% of cancer care providers assess tobacco use, less than 60% advise 
tobacco cessation, and less than 50% provide assistance with or make referrals for 
treatment (Price, Studts, & Hamann, 2018). Overall, it is clear that cancer survivors who 
are engaged in the cancer care system typically do not receive the high-quality, 
population-based tobacco treatment recommended by the foremost cancer care 
organizations.  
To address the problem of cancer survivors’ smoking via improvements in the 
capacity of cancer care facilities to provide evidence-based tobacco treatment, the 
National Cancer Institute (NCI) drew upon the Cancer Moonshot SM Program and 
launched the Cancer Center Cessation Initiative (National Cancer Institute, 2020). 
Beginning in 2017, 52 NCI-designated cancer centers received NCI funding to create or 
build upon existing tobacco treatment programs (Croyle, Morgan, & Fiore, 2019). 
Markey Cancer Center in Lexington, Kentucky used these funds to design, implement, 
and evaluate a multi-level intervention called the “Markey Cancer-specific Assessment, 
Referral, Engagement, and Support (CARES) Tobacco Treatment Program”. In the 
context of this program, this study has two objectives: 1) describe early implementation 
outcomes at the provider and patient level, specifically, rates of a) providers’ screening 
for tobacco use, b) patients’ using tobacco, and c) patients’ declining tobacco treatment 
referral, and 2) identify correlates of patients’ tobacco use and referral response. 
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CHAPTER 2. METHOD 
2.1 Participants 
 The sample consist of patients age 18 and older seen at Markey Cancer Center 
for an outpatient visit between July 1, 2018 and December 30, 2019, as this reflects the 
first 1½ years of implementation. A total of 26,365 unique patients comprise the sample, 
and they are drawn from each of the cancer center’s outpatient clinics (breast; 
gynecology; hematology; and multi-disciplinary (i.e., other tumor sites)). 
2.2 Procedures 
This study is a retrospective review of patients’ de-identified EMR. Implemented 
as standard of care for outpatient visits, the intake procedures require that all adults are 
questioned about their tobacco use and all responses are documented in the EMR. 
Questions allowed patients to be classified as never, former, or current (past month) 
tobacco users. Information about type of tobacco product was obtained if applicable. Any 
patient identified as a current tobacco user received an offer of assistance with tobacco 
cessation. Patients who accepted the offer were automatically e-referred to the cancer 
center’s Psych-Oncology Service where tobacco treatment specialists were charged with 
arranging treatment and following up. Patients who declined the offer were asked to 
provide a rationale (within a fixed set of response options) and advised to consider tobacco 
treatment in the future. All research procedures were approved by the University of 
Kentucky Institutional Review Board (Protocol 52059). 
2.3 Measures 
Data extracted from patients’ EMR includes: 1) demographic characteristics (age, 
sex, race, ethnicity, relationship status, and insurance type); 2) clinical parameters (clinic 
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setting and distress rating, as indicated on a scale from 0 = no distress to 10 = extreme 
distress (Roth et al., 1997)); and 3) tobacco use outcomes (Land et al., 2016). Tobacco 
use outcomes include: 1) rates of lifetime, former, and current tobacco use, 2) rates of 
tobacco use by product type, 3) rates of tobacco treatment referral acceptance and decline 
among current tobacco users, and 4) reasons for decline (i.e., reportedly already in 
treatment, wants to quit on his/her own, or not ready to quit) among the relevant 
subsample of current tobacco users. Implementation outcomes are current tobacco use, 
referral response, and reason for decline. 
2.4 Data Analysis 
Descriptive statistics were used to describe the sample characteristics and 
implementation outcomes. As appropriate, binomial (current tobacco use and referral 
response) and ordinal (reason for decline) logistic regression models were fit to examine 
the relationship between the implementation outcomes and relevant covariates 
(demographic and clinical characteristics). All covariates considered were categorical in 
nature with the exception of age and distress. Initial logistic modeling made use of a Box-
Tidwell transformation involving age and distress to assess linearity in the logit for these 
two covariates (Box & Tidwell, 1962); this linearity assumption was not tenable for any 
model. Therefore, tertile splits were used for age (< 55; 55-66; ³ 67) and distress (0; 1-5; 
6-10). All covariates were then entered simultaneously into the regression equations to 
assess their independent association with each implementation outcome. The deviance 
chi-square statistic assessed goodness of fit. The score test assessed the proportionality 
assumption for the ordinal model. The proportional odds assumption that is required for 
valid inference using the proportional odds model was violated given the significance of 
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the score test. Ultimately, reported results are based on the partial proportional odds 
model (Stokes, M. E., Davis, C. S., Koch, 2012) given that it was the most parsimonious 
and the proportional odds assumption appeared to be tenable for certain covariates. 
Model-adjusted odds ratios (OR) and 95% confidence intervals (CI) are reported. All 
statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC). 
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CHAPTER 3. RESULTS 
3.1 Sample Characteristics  
Table 1 details the sample’s (n = 26,365) demographic and clinical characteristics. 
Patients represent an array of disease sites/clinic settings (e.g., breast, hematology). 
About one-third of patients were male (36.43%, n = 9,604). Most patients were White 
non-Hispanic (93.11%, n = 24,150). Just over half of the sample was married or partnered 
(57.95%, n = 9,664). Medicare was the primary source of insurance coverage (44.24%, n 
= 7,631). The mean age was 59.32±14.34 years. The average level of distress was 
3.28±3.12, with 24.7% (n = 6,504) reporting clinically significant distress using a cut-off 
of 4 or higher (Roth et al., 1997). 
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TABLE 1. Demographic and Clinical Characteristics of the Patient Population (n = 26,365) a 
 
a Data are frequencies (percentages) unless otherwise noted.  
b Clinic where patient was seen at the time of tobacco use screening. “Other” denotes a 
multi-disciplinary clinic that sees patients with tumors in sites not otherwise specified. 
c Race and ethnicity were also combined such that there were White non-Latinx patients 
(n=23374) and racial/ethnic minority patients (n=2148). Missing data for this variable is 
n=843. 
d Missing data for these variables: race and ethnicity (n=428), marital status (n =9688), 
insurance status (n =9117), and distress (n =11097).  
e Data are means ±  standard deviations, medians. 
Characteristic Value 
Clinic b  
Gynecology 4267 (16.18%) 
Breast 4458 (16.91%) 
Hematology 4842 (18.37%) 
Other 12798 (48.54%) 
Sex  
Male 9604 (36.43%) 
Female 16761 (63.57%) 
Race c  
Native American 19 (0.07%) 
Hawaiian/Pacific Islander 24 (0.09%) 
Asian 182 (0.70%) 
Black or African American  1579 (6.08%) 
White 24150 (93.05%) 
Ethnicity c  
Latinx 417 (1.58%) 
Non-Latinx 25249 (95.77%) 
Missing 699 (2.65%) 
Relationship status d  
Separated 262 (1.58%) 
Widowed 1575 (9.44%) 
Divorced 2135 (12.80%) 
Single 3041 (18.23%) 
Married or partnered 9664 (57.95%) 
Insurance status d  
Self-pay/Other         478 (2.78%) 
Medicaid 3062 (17.75%) 
Managed care organization 6077 (35.23%) 
Medicare 7631 (44.24%) 
Age, years e 59.32 ± 14.34, 61 
Distress, 0-10 d, e 3.28 ± 3.12, 3 
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Table 2 presents the sample’s tobacco use characteristics. Nearly all (99.3%, n = 
26,183) patients were screened for tobacco use and had their response documented in the 
EMR. Lifetime tobacco use was reported by 43.82% (n = 11,551) of patients, and 
cigarettes were the most popular tobacco product among lifetime users (91.52%, n = 
10,571). Current tobacco use occurred in 48.04% (n = 5,549) of lifetime users or 21.05% 
(n = 5,549) of the full sample. Seventy-six percent (n = 4,250) of current users declined 
the offer of tobacco treatment. Of those who declined, the majority (65.84%, n = 2,798) 
said they were not ready to quit. 
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TABLE 2. Tobacco Use Characteristics of the Patient Population (n = 26,365) a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Data are frequencies (percentages) unless otherwise noted. 
 
 
 
 
 
Characteristic Value 
Lifetime history  
Current 5549 (21.05%)  
Former 6002 (22.77%) 
Never 14632 (55.50%) 
Missing 182 (0.69%) 
Last use among current and former users (n = 11,551)  
Today 4831 (41.82%)  
1 – 7 days ago 486 (4.21%) 
8 – 30 days ago 232 (2.01%) 
More than 1 month – 1 year ago 583 (5.05%) 
More than 1 year ago 5419 (46.91%) 
Product type among current and former users (n = 
11,551) 
 
Cigarettes 10571 (91.52%) 
Cigars or pipes 178 (1.54%) 
Electronic or vapes 138 (1.19%) 
Smokeless 517 (4.48%) 
Other, including multiple products 147 (1.27%)   
Tobacco treatment referral response among current 
users (n = 5,549)  
Decline 4250 (76.59%) 
Accept 956 (17.22%) 
Missing 343 (6.18%) 
Tobacco treatment referral response among current 
users who decline (n = 4,250)  
Already in treatment 269 (6.33%) 
Desire to quit without assistance 1148 (27.01%) 
Not ready to quit 2798 (65.84%) 
Other 35 (0.82%) 
11 
 
3.2 Associations with Implementation Outcomes 
3.2.1  Current Tobacco Use 
Patients from the gynecology (OR = 1.22; 95% CI, 1.04-1.43) and other 
site/multidisciplinary clinic (OR = 1.73; 95% CI, 1.53-1.95) were more likely to be 
tobacco users than patients from the hematology clinic. Males were almost twice as likely 
than females to be tobacco users (OR = 1.75; 95% CI, 1.58-1.94). Racial and ethnic 
minorities were less likely than Whites to be tobacco users (OR = 0.76; 95% CI, 0.65-
0.90). Compared to patients in a relationship, those who were single (OR = 1.41; 95% CI, 
1.26-1.58) and those who were divorced, separated, or widowed (OR = 1.67; 95% CI, 
1.50-1.86) were about one-and-a-half times more likely to be tobacco users. Regarding 
insurance status, compared to self-pay patients, those with Medicaid were nearly twice as 
likely to be current tobacco users (OR = 1.94; 95% CI, 1.47-2.55) while those with 
insurance from managed care organizations were much less likely (OR = 0.65; 95% CI, 
0.49-0.85). As age increased, patients were more likely to be tobacco users (OR = 0.79; 
95% CI, 0.71-0.87; OR = 0.30; CI, 0.26-0.35). Finally, those with distress scores ³ 6 
were nearly twice as likely to be tobacco users than those with no distress (OR = 1.84; 
95% CI, 1.66-2.05). 
3.2.2  Referral Decline 
Neither clinic, race and ethnicity, relationship status, insurance type, age nor 
distress level was associated with patients’ decision to decline or accept a referral for 
tobacco treatment. However, males were more likely to decline than females (OR = 1.59; 
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95% CI, 1.26-2.00) and patients with distress scores ³ 6 were less likely to decline 
treatment (OR = 0.61; 95% CI, 0.48-2.05). 
3.2.3 Reason for Referral Decline 
The cumulative logits model was fit for the ordinal reason for decline outcome. 
Given that this outcome contained three levels (‘not ready to quit’, wants to quit on 
her/his own’, and ‘already to treatment’), the logits formed include (1) the log odds of 
‘not ready to quit’ versus ‘quit without assistance’ or ‘already in treatment’ and (2) the 
log odds of ‘not ready to quit’ or ‘quit without assistances’ versus already in treatment’. 
This model assesses associations across the two logits using odds ratios that can be 
interpreted as comparing ‘least desirable’ outcome relative to ‘most desirable’ outcome. 
Neither race/ethnicity, relationship status, insurance status, nor age were associated with 
reason for decline. Relative to hematology clinic patients, gynecologic and other 
site/multidisciplinary clinic patients were associated with more favorable odds of reason 
for treatment referral decline for one of both sets of logits (other site for the first logit: 
OR = 0.69; 95% CI, 0.54-0.89 and gynecologic for the second logit: OR = 0.57; 95% CI, 
0.32-0.99). Male gender was associated with less favorable outcomes than females with 
regard to the second logit (OR = 1.96; 95% CI, 1.28-2.99). Relative to those with lower 
levels of distress, patients with higher levels were associated with more favorable odds of 
reason for treatment referral decline for the second logit (distress scores 1-5: OR = 0.48; 
95% CI, 0.30-0.79; distress scores 6-10: OR = 0.59; 95% CI, 0.37-0.93).
      
  
 
 
 
TABLE 3. Association of Cancer Patients’ Tobacco Use and Tobacco Treatment Referral Response 
 Current Tobacco Use Treatment Referral Decline Reason for Treatment Referral Decline 
   Logit 1 Logit 2 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Clinic/Disease site      
Hematology REF REF REF REF 
Breast 0.92 (0.78–1.09) 1.11 (0.75-1.64) 0.85 (0.60-1.22) 0.81 (0.42-1.59) 
Gynecology 1.22 (1.04–1.43)* 1.26 (0.88-1.79) 1.36 (0.97-1.88) 0.57 (0.32-0.99)* 
Other 1.73 (1.53–1.95)* 0.84 (0.64-1.11) 0.69 (0.54-0.89)* 0.80 (0.48-1.35) 
Sex     
Female REF REF REF REF 
Male 1.75 (1.58–1.94)* 1.59 (1.26-2.00)* 1.23 (0.99-1.52) 1.96 (1.28-2.99)* 
Race and ethnicity     
White, non-Hispanic REF REF REF -- 
Minority 0.76 (0.65–0.90)* 0.74 (0.53-1.05) 1.03 (0.74-1.43)  
Relationship Status     
Married or partnered REF REF REF -- 
Divorced, separated, 
widowed 
1.67 (1.50–1.86)* 1.08 (0.85-1.36) 0.91 (0.73-1.12)  
Single 1.41 (1.26–1.58)* 1.10 (0.86-1.42) 0.87 (0.70-1.09)  
Insurance status     
Self-pay/Other REF REF REF REF 
Managed care organization 0.65 (0.49–0.85)* 1.02 (0.54-1.93) 0.79 (0.45-1.39) 0.42 (0.10-1.74) 
Medicare 1.25 (0.95–1.65) 0.98 (0.52-1.85) 0.92 (0.53-1.61) 0.56 (0.14-2.31) 
Medicaid 1.94 (1.47-2.55)* 0.87 (0.46-1.63) 1.09 (0.62-1.91) 0.37 (0.09-1.49) 
Age tertiles     
< 55 years REF REF REF REF 
55-66 years 0.79 (0.71–0.87* 0.87 (0.70-1.09) 1.12 (0.91-1.37) 0.71 (0.49-1.02) 
³ 67 years 0.30 (0.26-0.35)* 0.82 (0.59-1.14) 1.35 (0.99-1.83) 1.10 (0.58-2.07) 
Distress tertiles     
0 REF REF REF REF 
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a Asterisk (*) denotes statistical significance. 
b The two logits are formed by fitting a cumulative logits model where the first logit corresponds to the ‘log odds’ of not yet 
ready to quit versus quit on my own or already in treatment and the second logit corresponds to the ‘log odds’ of not yet ready 
to quit or quit on my own versus already in treatment. These log odds ‘accumulate’ probability of ‘least desired to most desired 
outcome’. The model reported is the partial proportional odds/cumulative logits model. When odds ratio estimates appear in 
the logit1 column only, this implies that the proportional odds assumption was tenable and only one odds ratio is needed to 
quantify the effect of this covariate on the ordinal outcome of ‘reason for refusal’ of treatment. When the proportional odds 
assumption is not tenable, two sets of odds ratios are needed for the covariate and are reported separately for the two logits. 
Therefore, the last 2 columns provide results from a ‘partial’ proportional odds model where the proportional odds assumptions 
held for race/ethnicity and relationship status, but not for clinic, sex, insurance status, age tertiles, and distress tertiles. 
CI = confidence interval; OR = odds ratio; REF = reference category 
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CHAPTER 4.  DISCUSSION 
Recommendations by the foremost cancer care organizations to conduct 
population-based tobacco use assessment and provide evidence-based tobacco treatment 
are inadequately met by cancer care facilities, and smoking rates among cancer patients 
remain high (Shields et al., 2018; Toll et al., 2013). In the context of a new tobacco 
treatment program at a NCI-designated cancer center, this study aimed to determine rates 
and correlates of tobacco use, tobacco treatment referral decline, and reasons for decline, 
all with the goal of better understanding of how to optimize the reach of tobacco 
treatment in cancer settings. This study is the first to systematically examine reasons for 
declining enrollment into a cancer center’s integrated tobacco treatment program. 
Additionally, this study is one of the first to examine correlates of not only cancer 
patients’ tobacco use but also their treatment referral response and reasons for referral 
refusal. Finally, by measuring time since last use and non-cigarette tobacco use in 
addition to cigarette smoking among every cancer patient at every visit, the breadth and 
precision in the description of cancer patients’ tobacco use history is high.  
Three major study findings emerge. First, approximately 20% of adult cancer 
patients reported tobacco use. This converges with the upper-limits of both U.S. 
population-based survey data, which shows 9-19% of cancer patients are current smokers 
(Gallaway et al., 2019; Mayer & Carlson, 2011; Swoboda et al., 2019; Westmaas et al., 
2014), and data from 13 NCI-designated cancer centers, where current smoking rates 
range from 4 to 22% (Angelo et al., 2019; Davis, Thomas, Dirkes, & Swartzwelder, 
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2020; Gali et al., 2020; May et al., 2020; Ramsey et al., 2020). In addition to reinforcing 
concerns about cancer patients’ persistent cigarette smoking, this study also highlights the 
problem of non-cigarette tobacco use. Although only 1% of cancer patients in this study 
engaged in this behavior, other recent studies have found 3-25% of cancer patients are 
current users of electronic cigarettes (Akinboro et al., 2019; Borderud, Li, Burkhalter, 
Sheffer, & Ostroff, 2014) and in the general population these rates are on the rise 
(Creamer, Wang, & Babb, 2019), in part because smokers view these products as a means 
to smoking cessation (James, Cheney, Smith, & Beebe, 2019). Smoking and other 
tobacco use is clearly a deeply entrenched problem–even after the potential “teachable 
moment” of cancer diagnosis (McBride, Emmons, & Lipkus, 2003; McBride & Ostroff, 
2003)–a problem that cannot be ignored by cancer care providers due to fears of upsetting 
patients or perceptions of inadequate training on the matter (Nath Simmons et al., 2013; 
Warren, Marshall, et al., 2013). As a whole, the aforementioned tobacco use rates among 
cancer patients underscore the need for cancer care providers to ask every patient at every 
visit about their tobacco use and advise tobacco users to quit consistent with indicators of 
quality healthcare delivery (Patnode et al., n.d.) and current best practices for cancer care 
(Shields et al., 2018; Toll et al., 2013). There might even be sufficient reason to extend 
core items of the Cancer Patient Tobacco Use Questionnaire to include questions about 
non-cigarette tobacco use (Doyle et al., 2009; Toll et al., 2013) and to consider extending 
eligibility for clinical trials and treatment programs to all tobacco users, as opposed to a 
singular focus on cigarettes/smokers as is normative (Dahm et al., 2019; Japuntich et al., 
2016; Ostroff et al., 2014). In trying to reach the target audience for tobacco treatment, 
the results of this study would point toward a focus on cancer patients who were treated 
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in gynecology and multi-disciplinary clinics; are male; are not in a relationship; have 
Medicaid insurance; and report high distress – all of which is consistent with past studies 
on correlates of smoking status in cancer patients (Gallaway et al., 2019; Kanera et al., 
2019; Little et al., 2018). 
The second key study finding is that over three-quarters of tobacco users declined 
a referral for tobacco treatment that was integrated into the cancer care system. The rate 
of treatment acceptance in this study (17%) is much lower than that found in clinical 
trials for smoking cessation in cancer patients, which range from 17% to 84% (Dahm et 
al., 2019; Duffy, Scheumann, Fowler, Darling-Fisher, & Terrell, 2010; Gritz et al., 1991; 
Martinez et al., 2019; Ostroff et al., 2014). This rate is also in the lower limit of 
enrollment rates found for other cancer centers’ tobacco treatment programs, which range 
from 17% to 83% (Amato et al., 2018; Davis et al., 2020; Gali et al., 2020; Japuntich et 
al., 2016; Schnoll, Rothman, Lerman, et al., 2004; Schnoll, Rothman, Newman, et al., 
2004). The discrepancy between this study and prior ones could be due to the population-
based, proactive approach of this tobacco treatment program (i.e., an offer of assistance is 
made to every current tobacco user) compared with only offering treatment to tobacco 
users who ask for help or who report readiness to quit, as is customary in smoking 
cessation research (Westmaas, Berg, Alcaraz, & Stein, 2015) and some clinical 
implementation (Gritz et al., 1991). By offering treatment to “all comers,” one would 
likely expect a high rate of decline/low rate of acceptance, as most tobacco users–while 
interested in quitting at some point–are not ready to quit in the near future (Babb, 
Malarcher, Schauer, Asman, & Jamal, 2017; Burris, Wahlquist, & Carpenter, 2013). 
Indeed, in terms of reasons for refusal, most patients in this study declined treatment 
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because they were not ready to quit. Cancer patients who continue to smoke post-
diagnosis experience many barriers to quitting (e.g., stress of diagnosis, insufficient 
knowledge or appreciation of the impact of smoking on cancer outcomes, continued 
exposure to other tobacco users) (Borger et al., n.d.; Wells et al., 2017; Westmaas et al., 
2015), and it may be advantageous to offer assistance with tobacco cessation alongside 
assistance with interventions for distress management, unmet information or practical 
needs, and difficulty with role changes or family disruption. Interestingly, for cancer 
patients who were ready to quit, tobacco treatment referral was often declined due to the 
desire to quit on one’s own. Again, this is consistent with prior studies in that most 
tobacco users attempt to quit sans treatment, with many citing practical barriers to 
treatment use (e.g., financial cost, medication side-effects) (Morphett, Partridge, Gartner, 
Carter, & Hall, 2015; Smith, Carter, Dunlop, & Freeman, 2015) in addition to a 
prevailing preference to rely on one’s internal strength to overcome nicotine dependence 
(Borger et al., n.d.; Morphett et al., 2015), both issues that cancer care facilities will need 
to address in efforts to fully engage cancer patients in tobacco cessation. 
The final key finding concerns correlates of referral response. Patients were 
significantly more likely to decline tobacco treatment if they were male. This supports 
results from past studies that have found male gender to be a significant predictor of 
cancer patients’ declining tobacco treatment (Schnoll, Rothman, Lerman, et al., 2004; 
Sheffer et al., 2020). This study also found patients with higher levels of distress were 
less likely to decline tobacco treatment, which is contrary to some prior research (Sheffer 
et al., 2020), but possibly consistent with the affective response component of the 
“teachable moment” heuristic (McBride & Ostroff, 2003; McBride et al., 2008). Notably, 
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no other variables were significantly associated with treatment referral decline, possibly a 
function of the difficulties in predicting a high overall rate of refusal. Upon examining 
covariate associations with reasons for refusal, cancer patients were less likely to report 
readiness to quit if they were male, and more likely to report readiness to quit if they 
were treated in gynecology or multi-disciplinary clinics or reported higher levels of 
distress. Past studies have not found demographic characteristics or clinical variables to 
be significant predictors of quit motivation, but have found tobacco use variables (e.g., 
nicotine dependence) to play a role (Schnoll, Rothman, Newman, et al., 2004). No past 
studies have studied cancer patients’ distress level as a correlate of declining tobacco 
treatment in the context of a clinical trial or tobacco treatment program. Depressive 
symptoms and other markers of distress have been studied as a correlate of cancer 
survivors’ confidence to quit (Duffy, Karvonen-Gutierrez, Ewing, & Smith, 2010; 
Martinez et al., 2019) and readiness to quit (Schnoll et al., 2003), with significant 
negative associations, which contrast the findings of this study. Because many cancer 
patients experience distress during the acute period of cancer diagnosis and treatment 
(Carlson et al., 2019), integrating psychological services into cancer care might help 
patients capitalize on any affect-related motivation to quit while also preventing any 
distress that might eventually become a barrier to successful engagement in tobacco 
treatment. As is, further elucidation of demographic and clinical variables tied to tobacco 
treatment acceptance and readiness to quit is important, as it could lead to more targeted 
offers and tailored interventions, which could prove more cost-effective than a one-size-
fits-all approach to tobacco treatment. 
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The implementation outcomes of this study must be viewed in light of the study’s 
methodology and limitations. First, clinical service technicians were responsible for 
screening for tobacco use and offering cessation assistance. On the one hand, because 
patients may feel more pressure to accept tobacco treatment when asked by an oncologist 
or nurse (Hoover et al., 2019), the referral acceptance rates observed here might be 
especially low due to the nature of who asked the important questions. On the other hand, 
patients in this study may have felt more at ease and perhaps were more honest about 
their tobacco use and treatment readiness due to less perceived stigma or blame since the 
person asking about their tobacco behavior was not the person providing their cancer care 
(Shen Johnson, Hamann, Thomas, & Ostroff, 2017). Second, none of the predictive 
models are comprehensive. Since the data were pulled from patients’ EMR, data on some 
of the known predictors of current tobacco use and treatment acceptance (e.g., nicotine 
dependence, quit attempt history, risk perception, confidence to quit) were not available 
for analysis (Schnoll, Rothman, Newman, et al., 2004) while others (namely, disease site) 
were not detailed enough to provide definitive answers about their role in the 
implementation outcomes. That said, the correlates considered herein are largely 
consistent with those in similar studies (Burris et al., 2013; Schnoll, Rothman, Newman, 
et al., 2004; Sheffer et al., 2020). Third, and also related to the constraints of the study 
design, there was sizeable data missing for relationship status, insurance status, and 
distress level. 
Even with its limitations, this population-based study of more than 25,000 adults 
provides new information about cancer patients’ tobacco use, interest in tobacco 
treatment, and readiness to quit. Study findings underscore the need for cancer care 
21 
 
facilities to ask cancer patients about all forms of tobacco use and among those patients 
who report tobacco use, to stress the critical importance of tobacco cessation as an 
integral component of high-quality cancer treatment. Given limited resources in many 
cancer centers, the results of this and other studies should be used to guide cost-effective 
implementation of population-based tobacco use screening and proactive tobacco 
treatment that reaches wide swatches of the target patient population and engages people 
throughout the tobacco cessation process from making an initial quit attempt to achieving 
long-term abstinence. Ultimately, tobacco treatment is cancer treatment, and this study 
shows there is still room for improvement before the goals of the NCI Cancer Center 
Cessation Initiative are met.
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